-
Innovation Ranking
NewInnovation Ranking – NeuroBo Pharmaceuticals Inc
NeuroBo Pharmaceuticals Inc (NeuroBo), formerly Gemphire Therapeutics Inc, is a clinical stage biopharmaceutical company that focuses on developing novel therapeutics for neurodegenerative and cardiometabolic diseases. The company has pipeline product candidates include ANA001, an oral niclosamide formulation developed for moderate coronavirus disease (COVID-19 which is phase 2 clinical trials. Gemcabene for the treatment of homozygous familial hypercholesterolemia (HoFH) and hypertriglyceridemia (SHTG) which is a serious medical condition that increases the risk of life-threatening cardiovascular diseases; NB-01 for painful diabetic neuropathy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DA-1241 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DA-1241 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DA-1241 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: DA-1241 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRT-3645 in Oral Cavity (Mouth) Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PRT-3645 in Oral Cavity (Mouth) Cancer Drug Details: PRT-3645 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DA-1241 in Type 2 Diabetes
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DA-1241 in Type 2 Diabetes Drug Details: DA-1241 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DA-1241 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DA-1241 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DA-1241 in Non-Alcoholic Steatohepatitis (NASH) Drug Details: DA-1241 is under development...